Upstream Bio (UPB) Financials

Upstream Bio logo
$2.10 -0.05 (-2.33%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$2.10 0.00 (0.00%)
As of 03:59 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for Upstream Bio

Annual Income Statements for Upstream Bio

This table shows Upstream Bio's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-38 -76 -143
Consolidated Net Income / (Loss)
-21 -63 -143
Net Income / (Loss) Continuing Operations
-21 -63 -143
Total Pre-Tax Income
-21 -63 -143
Total Operating Income
-40 -78 -160
Total Gross Profit
2.38 2.37 2.85
Total Revenue
2.38 2.37 2.85
Operating Revenue
2.38 2.37 2.85
Total Cost of Revenue
0.00 0.00 0.00
Total Operating Expenses
42 80 163
Selling, General & Admin Expense
11 17 26
Research & Development Expense
32 63 137
Total Other Income / (Expense), net
20 15 17
Interest & Investment Income
4.17 12 17
Other Income / (Expense), net
15 2.84 -0.02
Preferred Stock Dividends Declared
18 14 0.00
Basic Earnings per Share
($12.95) ($5.58) ($2.66)
Weighted Average Basic Shares Outstanding
2.95M 13.68M 53.85M
Diluted Earnings per Share
($12.95) ($5.58) ($2.66)
Weighted Average Diluted Shares Outstanding
2.95M 13.68M 53.85M
Weighted Average Basic & Diluted Shares Outstanding
- 53.64M 54.42M

Quarterly Income Statements for Upstream Bio

This table shows Upstream Bio's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Total Costs & Expenses
- - - - - - 39 - - - 44
Net Income / (Loss) Attributable to Common Shareholders
-14 -20 -21 -22 -27 -40 -34 -42 -41 -40 -41
Consolidated Net Income / (Loss)
-11 -15 -16 -21 -27 -40 -34 -42 -41 -40 -41
Net Income / (Loss) Continuing Operations
-11 -15 -16 -21 -27 -40 -34 -42 -41 -40 -41
Total Pre-Tax Income
-11 -15 -16 -21 -27 -40 -34 -42 -41 -40 -41
Total Operating Income
-15 -18 -19 -26 -32 -44 -38 -46 -44 -42 -43
Total Gross Profit
0.64 0.51 0.61 0.61 0.57 0.94 0.68 0.67 1.03 0.77 0.40
Total Revenue
0.64 0.51 0.61 0.61 0.57 0.94 0.68 0.67 1.03 0.77 0.40
Operating Revenue
0.64 0.51 0.61 0.61 0.57 0.94 0.68 0.67 1.03 0.77 0.40
Total Cost of Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Operating Expenses
16 18 20 27 33 45 39 47 45 43 44
Selling, General & Admin Expense
3.96 3.98 4.07 5.16 6.78 7.42 5.54 6.67 8.08 7.05 7.17
Research & Development Expense
12 14 15 22 26 38 33 40 37 36 37
Total Other Income / (Expense), net
4.12 2.86 2.90 5.08 4.74 4.38 4.09 3.71 3.02 2.67 2.19
Interest & Investment Income
1.27 2.88 2.90 5.08 4.74 4.43 4.11 3.65 3.05 2.66 2.23
Other Income / (Expense), net
2.85 -0.02 -0.00 - 0.00 -0.05 -0.02 0.05 -0.03 0.01 -0.04
Basic Earnings per Share
($4.68) ($6.50) ($6.96) $12.56 ($0.51) ($0.74) ($0.63) ($0.78) ($0.75) ($0.73) ($0.75)
Weighted Average Basic Shares Outstanding
3.00M 3.01M 3.02M 13.68M 53.62M 53.77M 53.93M 53.85M 54.33M 54.57M 54.78M
Diluted Earnings per Share
($4.68) ($6.50) ($6.96) $12.56 ($0.51) ($0.74) ($0.63) ($0.78) ($0.75) ($0.73) ($0.75)
Weighted Average Diluted Shares Outstanding
3.00M 3.01M 3.02M 13.68M 53.62M 53.77M 53.93M 53.85M 54.33M 54.57M 54.78M
Weighted Average Basic & Diluted Shares Outstanding
- - 53.60M 53.64M 53.79M 53.91M 54.04M 54.42M 54.42M 54.77M 54.81M

Annual Cash Flow Statements for Upstream Bio

This table details how cash moves in and out of Upstream Bio's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
19 300 -224
Net Cash From Operating Activities
-38 -59 -133
Net Cash From Continuing Operating Activities
-38 -56 -133
Net Income / (Loss) Continuing Operations
-21 -63 -143
Consolidated Net Income / (Loss)
-21 -63 -143
Depreciation Expense
0.06 0.09 0.19
Amortization Expense
-1.26 -1.66 -1.50
Non-Cash Adjustments To Reconcile Net Income
-12 6.19 10
Changes in Operating Assets and Liabilities, net
-4.31 1.87 1.15
Net Cash From Investing Activities
-83 -59 -93
Net Cash From Continuing Investing Activities
-83 -59 -93
Purchase of Property, Plant & Equipment
-0.14 -0.51 -0.17
Purchase of Investments
-129 -291 -386
Sale and/or Maturity of Investments
46 232 293
Net Cash From Financing Activities
130 419 2.44
Net Cash From Continuing Financing Activities
140 423 2.44
Repurchase of Preferred Equity
0.00 - -0.03
Issuance of Preferred Equity
139 150 0.00
Issuance of Common Equity
0.00 273 0.20
Other Financing Activities, net
0.12 0.16 2.28

Quarterly Cash Flow Statements for Upstream Bio

This table details how cash moves in and out of Upstream Bio's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
5.68 16 -14 293 -255 -26 27 29 -4.85 -17 -32
Net Cash From Operating Activities
-18 -8.04 -14 -20 -41 -39 -22 -31 -48 -36 -54
Net Cash From Continuing Operating Activities
-18 -8.04 -14 -17 -41 -39 -22 -31 -48 -36 -54
Net Income / (Loss) Continuing Operations
-11 -15 -16 -21 -27 -40 -34 -42 -41 -40 -41
Consolidated Net Income / (Loss)
-11 -15 -16 -21 -27 -40 -34 -42 -41 -40 -41
Depreciation Expense
0.01 0.01 0.01 0.05 0.04 0.04 0.05 0.06 0.05 0.05 0.05
Amortization Expense
-0.62 -1.14 -0.57 0.68 -1.74 -0.99 -0.15 1.37 -0.75 -0.04 -0.42
Non-Cash Adjustments To Reconcile Net Income
-2.20 1.39 1.92 5.08 2.77 2.46 2.60 2.50 4.80 4.51 4.51
Changes in Operating Assets and Liabilities, net
-3.86 6.38 0.67 -1.32 -15 -0.79 9.02 7.90 -11 -0.44 -17
Net Cash From Investing Activities
14 -117 1.41 42 -213 13 48 59 42 16 22
Net Cash From Continuing Investing Activities
14 -117 1.41 42 -213 13 48 59 42 16 22
Purchase of Investments
-23 -152 -73 -42 -266 -57 -24 -38 -14 -51 -16
Sale and/or Maturity of Investments
37 35 75 84 53 70 73 97 57 67 38
Net Cash From Financing Activities
9.39 141 -1.64 271 -0.03 0.61 0.76 1.10 0.60 2.53 0.07
Net Cash From Continuing Financing Activities
9.39 141 -1.64 275 -0.03 0.61 0.76 1.10 0.60 2.53 0.07
Issuance of Common Equity
- - - - - - - - - - 0.07

Annual Balance Sheets for Upstream Bio

This table presents Upstream Bio's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Total Assets
117 482 354
Total Current Assets
117 479 352
Cash & Equivalents
26 326 102
Short-Term Investments
84 145 240
Accounts Receivable
0.10 0.61 0.67
Prepaid Expenses
7.09 8.10 9.62
Plant, Property, & Equipment, net
0.16 0.58 0.56
Total Noncurrent Assets
0.04 1.98 1.42
Other Noncurrent Operating Assets
0.04 1.98 1.42
Total Liabilities & Shareholders' Equity
117 482 354
Total Liabilities
9.39 12 14
Total Current Liabilities
6.52 11 13
Accounts Payable
1.99 4.04 2.73
Accrued Expenses
4.48 5.99 10
Other Current Liabilities
0.05 0.70 0.72
Total Noncurrent Liabilities
2.87 1.13 0.55
Other Noncurrent Operating Liabilities
2.87 1.13 0.55
Commitments & Contingencies
0.00 0.00 0.00
Total Equity & Noncontrolling Interests
-123 470 340
Total Preferred & Common Equity
-123 470 340
Preferred Stock
0.00 0.00 0.00
Total Common Equity
-123 470 340
Common Stock
4.83 661 673
Retained Earnings
-128 -191 -334
Accumulated Other Comprehensive Income / (Loss)
0.02 -0.03 0.53

Quarterly Balance Sheets for Upstream Bio

This table presents Upstream Bio's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
233 456 421 391 318 281 246
Total Current Assets
227 454 418 389 316 280 245
Cash & Equivalents
33 71 45 72 97 79 47
Short-Term Investments
188 360 348 300 198 182 160
Accounts Receivable
0.61 0.57 0.94 0.68 1.03 0.77 0.40
Prepaid Expenses
6.01 22 24 16 21 18 37
Plant, Property, & Equipment, net
0.58 0.54 0.54 0.62 0.51 0.46 0.41
Total Noncurrent Assets
4.85 1.84 1.71 1.56 1.27 1.11 0.95
Other Noncurrent Operating Assets
4.85 1.84 1.71 1.56 1.27 1.11 0.95
Total Liabilities & Shareholders' Equity
233 456 421 391 318 281 246
Total Liabilities
12 11 12 13 14 10 12
Total Current Liabilities
11 9.57 11 12 14 9.99 12
Accounts Payable
4.90 4.72 2.55 3.95 1.71 2.31 2.39
Accrued Expenses
5.30 4.14 7.67 7.24 11 6.95 8.84
Other Current Liabilities
0.68 0.71 0.71 0.72 0.72 0.73 0.73
Total Noncurrent Liabilities
1.26 0.99 0.85 0.70 0.39 0.23 0.06
Other Noncurrent Operating Liabilities
1.26 0.99 0.85 0.70 0.39 0.23 0.06
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
-160 446 409 379 304 271 234
Total Preferred & Common Equity
-160 446 409 379 304 271 234
Preferred Stock
- 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
-160 446 409 379 304 271 234
Common Stock
8.88 663 667 670 679 686 690
Retained Earnings
-170 -218 -258 -292 -375 -415 -456
Accumulated Other Comprehensive Income / (Loss)
0.35 0.37 0.26 0.49 0.10 -0.12 -0.33

Annual Metrics And Ratios for Upstream Bio

This table displays calculated financial ratios and metrics derived from Upstream Bio's official financial filings.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
- - 54,038,591.00
DEI Adjusted Shares Outstanding
- - 54,038,591.00
DEI Earnings Per Adjusted Shares Outstanding
- - -2.65
Growth Metrics
- - -
Revenue Growth
0.00% -0.42% 20.42%
EBITDA Growth
0.00% -195.32% -111.37%
EBIT Growth
0.00% -203.33% -114.04%
NOPAT Growth
0.00% -93.86% -106.22%
Net Income Growth
0.00% -205.82% -128.39%
EPS Growth
0.00% 56.91% 52.33%
Operating Cash Flow Growth
0.00% -56.02% -125.23%
Free Cash Flow Firm Growth
0.00% 0.00% -99.00%
Invested Capital Growth
0.00% 70.07% -190.15%
Revenue Q/Q Growth
0.00% 0.00% 1.97%
EBITDA Q/Q Growth
0.00% 0.00% -13.39%
EBIT Q/Q Growth
0.00% 0.00% -14.08%
NOPAT Q/Q Growth
0.00% 0.00% -14.13%
Net Income Q/Q Growth
0.00% 0.00% -17.36%
EPS Q/Q Growth
0.00% 0.00% -124.91%
Operating Cash Flow Q/Q Growth
0.00% 0.00% -9.01%
Free Cash Flow Firm Q/Q Growth
0.00% 0.00% 0.00%
Invested Capital Q/Q Growth
0.00% 0.00% -128.23%
Profitability Metrics
- - -
Gross Margin
100.00% 100.00% 100.00%
EBITDA Margin
-1,088.32% -3,227.64% -5,665.38%
Operating Margin
-1,685.46% -3,281.18% -5,618.82%
EBIT Margin
-1,037.90% -3,161.56% -5,619.34%
Profit (Net Income) Margin
-862.90% -2,650.04% -5,026.03%
Tax Burden Percent
100.00% 100.00% 100.00%
Interest Burden Percent
83.14% 83.82% 89.44%
Effective Tax Rate
0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00%
Return on Equity (ROE)
-19.05% -21.74% -35.43%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
-21.08% -25.02% -38.39%
Return on Assets (ROA)
-17.52% -20.97% -34.34%
Return on Common Equity (ROCE)
21.76% -13.05% -35.43%
Return on Equity Simple (ROE_SIMPLE)
16.68% -13.37% 0.00%
Net Operating Profit after Tax (NOPAT)
-28 -54 -112
NOPAT Margin
-1,179.82% -2,296.83% -3,933.17%
Net Nonoperating Expense Percent (NNEP)
6.87% -2.89% -7.68%
Return On Investment Capital (ROIC_SIMPLE)
22.81% -11.59% -33.04%
Cost of Revenue to Revenue
0.00% 0.00% 0.00%
SG&A Expenses to Revenue
449.37% 724.39% 925.33%
R&D to Revenue
1,336.09% 2,656.79% 4,793.48%
Operating Expenses to Revenue
1,785.46% 3,381.18% 5,718.82%
Earnings before Interest and Taxes (EBIT)
-25 -75 -160
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-26 -76 -162
Valuation Ratios
- - -
Price to Book Value (P/BV)
0.00 0.48 4.30
Price to Tangible Book Value (P/TBV)
0.00 0.48 4.30
Price to Revenue (P/Rev)
107.14 94.91 512.30
Price to Earnings (P/E)
0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
158.04 0.00 392.64
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00
Leverage & Solvency
- - -
Debt to Equity
0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00
Financial Leverage
-1.02 -1.00 -1.00
Leverage Ratio
1.09 1.04 1.03
Compound Leverage Factor
0.90 0.87 0.92
Debt to Total Capital
0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
214.21% 0.00% 0.00%
Common Equity to Total Capital
-114.21% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00
Altman Z-Score
15.22 11.48 60.99
Noncontrolling Interest Sharing Ratio
214.21% 39.98% 0.00%
Liquidity Ratios
- - -
Current Ratio
17.96 44.63 26.15
Quick Ratio
16.87 43.87 25.44
Cash Flow Metrics
- - -
Free Cash Flow to Firm (FCFF)
0.00 -56 -111
Operating Cash Flow to CapEx
-26,337.50% -11,579.65% -80,772.73%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00
Efficiency Ratios
- - -
Asset Turnover
0.02 0.01 0.01
Accounts Receivable Turnover
24.29 6.67 4.46
Inventory Turnover
0.00 0.00 0.00
Fixed Asset Turnover
14.97 6.40 5.00
Accounts Payable Turnover
0.00 0.00 0.00
Days Sales Outstanding (DSO)
15.03 54.75 81.91
Days Inventory Outstanding (DIO)
0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00
Cash Conversion Cycle (CCC)
15.03 54.75 81.91
Capital & Investment Metrics
- - -
Invested Capital
-2.00 -0.60 -1.74
Invested Capital Turnover
-1.19 -1.82 -2.44
Increase / (Decrease) in Invested Capital
0.00 1.40 -1.14
Enterprise Value (EV)
376 -246 1,121
Market Capitalization
255 225 1,462
Book Value per Share
($41.68) $8.77 $6.29
Tangible Book Value per Share
($41.68) $8.77 $6.29
Total Capital
108 470 340
Total Debt
0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00
Net Debt
-110 -470 -342
Capital Expenditures (CapEx)
0.14 0.51 0.17
Debt-free, Cash-free Net Working Capital (DFCFNWC)
0.67 -2.03 -3.16
Debt-free Net Working Capital (DFNWC)
110 468 338
Net Working Capital (NWC)
110 468 338
Net Nonoperating Expense (NNE)
-7.54 8.37 31
Net Nonoperating Obligations (NNO)
-110 -470 -342
Total Depreciation and Amortization (D&A)
-1.20 -1.57 -1.31
Debt-free, Cash-free Net Working Capital to Revenue
28.19% -85.57% -110.86%
Debt-free Net Working Capital to Revenue
4,642.06% 19,764.68% 11,855.12%
Net Working Capital to Revenue
4,642.06% 19,764.68% 11,855.12%
Earnings Adjustments
- - -
Adjusted Basic Earnings per Share
$0.00 ($5.58) ($2.66)
Adjusted Weighted Average Basic Shares Outstanding
0.00 13.68M 53.85M
Adjusted Diluted Earnings per Share
$0.00 ($5.58) ($2.66)
Adjusted Weighted Average Diluted Shares Outstanding
0.00 13.68M 53.85M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
0.00 53.64M 54.42M
Normalized Net Operating Profit after Tax (NOPAT)
-28 -54 -112
Normalized NOPAT Margin
-1,179.82% -2,296.83% -3,933.17%
Pre Tax Income Margin
-862.90% -2,650.04% -5,026.03%
Debt Service Ratios
- - -
EBIT to Interest Expense
0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00
Payout Ratios
- - -
Dividend Payout Ratio
0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Upstream Bio

This table displays calculated financial ratios and metrics derived from Upstream Bio's official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
- - - 53,596,601.00 - - - 54,038,591.00 54,419,986.00 54,419,986.00 54,771,041.00
DEI Adjusted Shares Outstanding
- - - 53,596,601.00 - - - 54,038,591.00 54,419,986.00 54,419,986.00 54,771,041.00
DEI Earnings Per Adjusted Shares Outstanding
- - - -0.41 - - - -0.79 -0.75 -0.73 -0.75
Growth Metrics
- - - - - - - - - - -
Revenue Growth
0.00% 0.00% -2.25% 0.00% -11.56% 83.73% 12.52% 8.97% 82.69% -17.50% -42.17%
EBITDA Growth
0.00% 0.00% -308.21% 0.00% -163.94% -142.67% -95.13% -74.64% -31.58% 6.59% -15.37%
EBIT Growth
0.00% 0.00% -308.21% 0.00% -163.26% -152.90% -100.32% -75.21% -36.34% 4.59% -14.71%
NOPAT Growth
0.00% 0.00% -101.29% 0.00% -113.24% -152.83% -100.25% -75.42% -36.24% 4.46% -14.66%
Net Income Growth
0.00% 0.00% -415.54% 0.00% -150.32% -172.29% -111.03% -99.88% -48.85% 0.66% -22.06%
EPS Growth
0.00% 0.00% -229.86% 0.00% 89.10% 88.62% 90.95% -106.21% -47.06% 1.35% -19.05%
Operating Cash Flow Growth
0.00% 0.00% 0.00% -21.74% -134.40% -388.29% -59.29% -56.19% -16.24% 9.22% -143.84%
Free Cash Flow Firm Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -149.35% 0.00% 29.81% 47.74% -55.23%
Invested Capital Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 6,513.54% -190.15% -33.83% -36.35% 332.19%
Revenue Q/Q Growth
0.00% -20.31% 0.00% 0.99% 0.00% 65.55% -27.11% -2.20% 54.79% -25.24% -48.90%
EBITDA Q/Q Growth
0.00% -46.31% 0.00% -31.53% 0.00% -34.52% 16.27% -17.71% 0.75% 4.51% -3.41%
EBIT Q/Q Growth
0.00% -44.37% 0.00% -39.28% 0.00% -38.68% 14.74% -21.82% 5.35% 2.94% -2.50%
NOPAT Q/Q Growth
0.00% -16.83% 0.00% -39.30% 0.00% -38.53% 14.69% -22.03% 5.53% 2.86% -2.39%
Net Income Q/Q Growth
0.00% -34.73% 0.00% -32.83% 0.00% -46.56% 15.56% -25.81% 4.40% 2.19% -3.75%
EPS Q/Q Growth
0.00% -38.89% 0.00% 280.46% 0.00% -45.10% 14.86% -23.81% 3.85% 2.67% -2.74%
Operating Cash Flow Q/Q Growth
-9.01% 54.24% 0.00% -40.47% -109.90% 4.68% 43.32% -37.73% -56.22% 25.56% -52.24%
Free Cash Flow Firm Q/Q Growth
0.00% 0.00% 0.00% 100.00% 0.00% -26.11% 29.15% 4.76% 17.52% 6.11% -110.47%
Invested Capital Q/Q Growth
0.00% 0.00% 0.00% -523.96% 0.00% 6.55% -59.39% -128.23% 641.77% 2.49% 175.75%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin
-1,995.31% -3,663.53% -3,113.01% -4,174.06% -5,954.95% -4,838.85% -5,557.98% -6,689.22% -4,289.17% -5,478.65% -11,087.59%
Operating Margin
-2,345.78% -3,439.22% -3,112.52% -4,293.31% -5,656.01% -4,732.87% -5,539.39% -6,911.23% -4,218.09% -5,480.98% -10,982.03%
EBIT Margin
-1,900.00% -3,442.16% -3,113.01% -4,293.31% -5,656.01% -4,738.21% -5,542.17% -6,903.14% -4,220.99% -5,480.08% -10,992.91%
Profit (Net Income) Margin
-1,702.19% -2,878.04% -2,634.60% -3,465.25% -4,818.02% -4,265.31% -4,941.14% -6,356.14% -3,925.63% -5,136.09% -10,428.35%
Tax Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent
89.59% 83.61% 84.63% 80.71% 85.18% 90.02% 89.16% 92.08% 93.00% 93.72% 94.86%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% -1,277.63% -1,189.99% -3,581.36% 0.00% -829.63% -976.65% -1,346.65%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% -1,275.38% -1,185.46% -3,578.91% 0.00% -826.86% -973.58% -1,342.92%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 1,234.65% 1,141.48% 3,542.71% 0.00% 800.78% 938.04% 1,271.08%
Return on Equity (ROE)
0.00% 0.00% 0.00% -21.74% -42.98% -48.51% -38.65% -35.43% -28.85% -38.61% -75.57%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -977.42% -914.69% -874.80%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% -33.98% -28.47% -30.68% -49.73% -47.16% -36.22% -49.33% -99.03%
Return on Assets (ROA)
0.00% 0.00% 0.00% -27.43% -24.25% -27.62% -44.34% -43.42% -33.69% -46.23% -93.94%
Return on Common Equity (ROCE)
0.00% 0.00% 0.00% -13.05% -42.98% -48.51% -14.08% -35.43% -28.85% -38.61% -75.57%
Return on Equity Simple (ROE_SIMPLE)
0.00% 0.00% 0.00% 0.00% -17.77% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-11 -12 -13 -18 -22 -31 -26 -32 -31 -30 -30
NOPAT Margin
-1,642.05% -2,407.45% -2,178.76% -3,005.32% -3,959.20% -3,313.01% -3,877.57% -4,837.86% -2,952.66% -3,836.69% -7,687.42%
Net Nonoperating Expense Percent (NNEP)
0.00% 0.00% -2.51% -0.60% -2.25% -4.53% -2.45% -2.50% -2.77% -3.07% -3.73%
Return On Investment Capital (ROIC_SIMPLE)
- - - -3.92% -5.03% -7.59% -7.00% -9.51% -10.04% -10.95% -12.98%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
619.06% 780.59% 670.02% 841.44% 1,198.23% 791.78% 811.42% 997.90% 781.82% 912.29% 1,813.92%
R&D to Revenue
1,826.72% 2,758.63% 2,542.50% 3,551.88% 4,557.77% 4,041.09% 4,827.96% 6,013.32% 3,536.27% 4,668.69% 9,268.10%
Operating Expenses to Revenue
2,445.78% 3,539.22% 3,212.52% 4,393.31% 5,756.01% 4,832.87% 5,639.39% 7,011.23% 4,318.09% 5,580.98% 11,082.03%
Earnings before Interest and Taxes (EBIT)
-12 -18 -19 -26 -32 -44 -38 -46 -44 -42 -43
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-13 -19 -19 -26 -34 -45 -38 -45 -44 -42 -44
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
0.00 0.00 0.00 0.48 0.74 1.44 2.68 4.30 1.61 1.39 1.23
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.48 0.74 1.44 2.68 4.30 1.61 1.39 1.23
Price to Revenue (P/Rev)
0.00 0.00 0.00 94.91 142.92 216.82 362.43 512.30 147.20 119.57 100.60
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 12.98 104.27 0.00 20.65 12.05 3.06
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 0.00 72.28 229.37 392.64 58.52 36.83 28.34
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
0.00 0.00 -1.00 -1.00 -0.97 -0.96 -0.99 -1.00 -0.97 -0.96 -0.95
Leverage Ratio
0.00 0.00 1.06 1.04 1.02 1.03 1.04 1.03 1.03 1.03 1.04
Compound Leverage Factor
0.00 0.00 0.89 0.84 0.87 0.93 0.93 0.95 0.96 0.97 0.99
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 172.68% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
0.00% 0.00% -72.68% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
0.00 0.00 0.00 11.81 18.92 30.04 48.07 62.06 19.92 20.78 12.39
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 39.98% 0.00% 0.00% 63.57% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
0.00 0.00 20.90 44.63 47.43 38.27 32.67 26.15 23.14 27.99 20.45
Quick Ratio
0.00 0.00 20.35 43.87 45.15 36.10 31.33 25.44 21.63 26.24 17.37
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
0.00 0.00 -13 0.00 -37 -46 -33 -31 -26 -24 -51
Operating Cash Flow to CapEx
0.00% 0.00% 0.00% -10,601.08% 0.00% 0.00% -34,750.00% -56,724.07% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.00 0.00 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01
Accounts Receivable Turnover
0.00 0.00 0.00 6.67 4.06 2.91 4.34 4.46 4.15 3.70 5.32
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00 6.40 4.26 5.01 4.69 5.00 6.33 6.29 5.59
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 54.75 89.98 125.60 84.11 81.91 87.90 98.76 68.55
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 54.75 89.98 125.60 84.11 81.91 87.90 98.76 68.55
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
0.00 0.00 -0.10 -0.60 14 15 6.16 -1.74 9.42 9.65 27
Invested Capital Turnover
0.00 0.00 0.00 -3.96 0.32 0.36 0.92 -2.44 0.28 0.25 0.18
Increase / (Decrease) in Invested Capital
0.00 0.00 -0.10 0.00 14 15 6.25 -1.14 -4.81 -5.51 20
Enterprise Value (EV)
0.00 0.00 415 -246 -103 197 642 1,121 194 116 81
Market Capitalization
255 255 255 225 328 590 1,014 1,462 489 378 289
Book Value per Share
$0.00 $0.00 ($53.03) $8.77 $8.31 $7.60 $7.02 $6.29 $5.59 $4.98 $4.27
Tangible Book Value per Share
$0.00 $0.00 ($53.03) $8.77 $8.31 $7.60 $7.02 $6.29 $5.59 $4.98 $4.27
Total Capital
0.00 0.00 221 470 446 409 379 340 304 271 234
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
0.00 0.00 -221 -470 -431 -394 -372 -342 -295 -261 -207
Capital Expenditures (CapEx)
0.00 0.00 0.00 0.19 0.00 0.00 0.06 0.05 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
0.00 0.00 -4.26 -2.03 13 14 4.68 -3.16 8.03 8.31 25
Debt-free Net Working Capital (DFNWC)
0.00 0.00 216 468 444 407 377 338 303 270 233
Net Working Capital (NWC)
0.00 0.00 216 468 444 407 377 338 303 270 233
Net Nonoperating Expense (NNE)
0.38 2.40 2.77 2.82 4.86 8.92 7.26 10 10 10 11
Net Nonoperating Obligations (NNO)
0.00 0.00 -221 -470 -431 -394 -372 -342 -295 -261 -207
Total Depreciation and Amortization (D&A)
-0.61 -1.13 0.00 0.73 -1.69 -0.94 -0.11 1.43 -0.71 0.01 -0.37
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00% -85.57% 559.23% 505.40% 167.27% -110.86% 241.75% 263.05% 881.81%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 19,764.68% 19,347.56% 14,959.35% 13,472.99% 11,855.12% 9,109.27% 8,537.49% 8,107.07%
Net Working Capital to Revenue
0.00% 0.00% 0.00% 19,764.68% 19,347.56% 14,959.35% 13,472.99% 11,855.12% 9,109.27% 8,537.49% 8,107.07%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$0.00 $0.00 ($6.96) $12.56 ($0.51) ($0.74) ($0.63) ($0.78) ($0.75) ($0.73) ($0.75)
Adjusted Weighted Average Basic Shares Outstanding
0.00 0.00 3.02M 13.68M 53.62M 53.77M 53.93M 53.85M 54.33M 54.57M 54.78M
Adjusted Diluted Earnings per Share
$0.00 $0.00 ($6.96) $12.56 ($0.51) ($0.74) ($0.63) ($0.78) ($0.75) ($0.73) ($0.75)
Adjusted Weighted Average Diluted Shares Outstanding
0.00 0.00 3.02M 13.68M 53.62M 53.77M 53.93M 53.85M 54.33M 54.57M 54.78M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
0.00 0.00 53.60M 53.64M 53.79M 53.91M 54.04M 54.42M 54.42M 54.77M 54.81M
Normalized Net Operating Profit after Tax (NOPAT)
-11 -12 -13 -18 -22 -31 -26 -32 -31 -30 -30
Normalized NOPAT Margin
-1,642.05% -2,407.45% -2,178.76% -3,005.32% -3,959.20% -3,313.01% -3,877.57% -4,837.86% -2,952.66% -3,836.69% -7,687.42%
Pre Tax Income Margin
-1,702.19% -2,878.04% -2,634.60% -3,465.25% -4,818.02% -4,265.31% -4,941.14% -6,356.14% -3,925.63% -5,136.09% -10,428.35%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Upstream Bio’s Q2 2026 statements show modest progress in reducing expenses and operating cash burn, but the company remains deeply unprofitable and dependent on its cash and investment portfolio to fund research and development.

  • Liquidity remains substantial: Cash and short-term investments totaled approximately $261.3 million at June 30, 2026. Although this was down from $294.6 million at March 31, 2026, it provides a meaningful funding base relative to the company’s quarterly operating cash burn.
  • Operating cash burn improved sequentially: Net cash used in operating activities declined to $35.6 million in Q2 2026 from $47.9 million in Q1 2026. It also improved from $39.2 million in Q2 2025.
  • Operating expenses are trending lower: Total operating expenses fell to $43.1 million in Q2 2026 from $44.6 million in Q1 2026 and $45.3 million in Q2 2025. Research and development spending declined modestly year over year to $36.1 million.
  • The balance sheet has limited leverage: Total liabilities were $10.2 million compared with $271.0 million of shareholders’ equity. The company reported no preferred stock balance and no material debt category in the provided statements.
  • Investment income continues to offset part of the operating deficit: Interest and investment income contributed $2.7 million in Q2 2026. This reduces the net loss, but it depends on the company’s investment balances and prevailing interest rates rather than core product revenue.
  • Upstream Bio remains deeply unprofitable: The company posted a $39.7 million net loss, or a loss of $0.73 per diluted share, in Q2 2026. It has reported sizable quarterly losses throughout the periods provided.
  • Revenue remains very small and declined year over year: Q2 2026 revenue was $773,000, down from $1.0 million in Q1 2026 and $937,000 in Q2 2025. Revenue is not yet sufficient to meaningfully offset research and operating costs.
  • Operating cash flow remains consistently negative: Despite the sequential improvement, the company used $35.6 million in operating cash during Q2. Continued clinical and corporate spending will reduce liquidity unless revenue increases, expenses decline further or new capital is raised.
  • Liquid resources have declined materially over the broader period: Cash and short-term investments fell from approximately $392.6 million at June 30, 2025, to $261.3 million at June 30, 2026. Total assets also declined from $420.5 million to $281.2 million over that period.
  • Accumulated losses and potential dilution remain concerns: Retained earnings were negative $414.5 million at June 30, 2026. Weighted-average basic shares increased to 54.6 million from 53.8 million in Q2 2025, indicating modest dilution while losses continue to accumulate.

Overall, Upstream Bio’s financial position remains supported by a sizable investment portfolio and low liabilities, while recent cost and cash-burn improvements are encouraging. However, the company has not demonstrated operating profitability, revenue has remained limited, and its declining liquidity means investors should closely monitor clinical spending, cash runway and the possibility of future financing.

11/18/26 04:38 AM ETAI Generated. May Contain Errors.

Upstream Bio Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Upstream Bio's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Upstream Bio's net income appears to be on a downward trend, with a most recent value of -$143.44 million in 2025, falling from -$20.54 million in 2023. The previous period was -$62.81 million in 2024. Find out what analysts predict for Upstream Bio in the coming months.

Upstream Bio's total operating income in 2025 was -$160.36 million, based on the following breakdown:
  • Total Gross Profit: $2.85 million
  • Total Operating Expenses: $163.22 million

Over the last 2 years, Upstream Bio's total revenue changed from $2.38 million in 2023 to $2.85 million in 2025, a change of 19.9%.

In the past 8 quarters, Upstream Bio's cash and equivalents has ranged from $32.95 million in Q3 2024 to $96.72 million in Q1 2026, and is currently $47.42 million as of their latest financial filing in Q3 2026.

Upstream Bio had total debt of $0.00 at the end of 2025, compared with none in 2024, and none in 2023.

Over the last 2 years, Upstream Bio's book value per share changed from -41.68 in 2023 to 6.29 in 2025.



Financial statements for NASDAQ:UPB last updated on 11/10/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners